'Bangavax' single-dose vaccine powerful against Covid-19: US medical journal
The world's first one-dose mRNA vaccine against the coronavirus (SARS-COV-2) produced by Globe Biotech Limited of Bangladesh has been published in the renowned US medical journal 'Vaccine'.
'Bangavax' may be the world's first powerful single-dosage vaccine made applying mRNA technology which has successfully displayed strong protection in individual cells and animals against the SARS-Cov-2 virus.
Globe Biotech Limited, a good Bangladeshi company, has developed this vaccine using its own technology found in tandem with world-renowned vaccine designers which also have Bangladesh to a distinctive height on the environment stage.
Regardless of the inherent limitations of employed in developing countries like Bangladesh, such as the management of recycleables, adaptation to new technologies, lack of study funds, etc. the vaccine originated by a good team of little scientists led by Dr. Nazneen Sultana and Kakon Nag.
Its unique design, technology and formulation have been able to create effective pharmacological reactions in animals.
Pre-clinical studies have demonstrated that this vaccine is usually tolerant and safe on individual cells and animals, and there is proof specific antibody production on the 7th day following vaccination, with the required dose on the 14th day. Adequate numbers of recollection cells were found for the initial 91 times after vaccination, indicating that the vaccine is capable of providing long-term security against the virus.
A complete of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There have been 8 situations of Covid-19 with onset at least seven days after the second dose among participants designated to get BNT162b2 and 162 conditions among those assigned to placebo; BNT162b2 was 95% powerful in protecting against Covid-19 (95% credible interval, 90.3 to 97.6). Identical vaccine efficacy (generally 90 to 100%) was observed across subgroups described by age, sex, competition, ethnicity, baseline body-mass index, and the occurrence of coexisting circumstances. Among 10 conditions of severe Covid-19 with onset following the first dose, 9 happened in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate discomfort at the injection webpage, fatigue, and headaches. The incidence of serious adverse occasions was low and was very similar in the vaccine and placebo teams.
This vaccine will be cheaper than other mRNA vaccines. So, it will be less expensive to low- and middle-income countries.
